BioAffinity Research And Ddevelopement To Revenue from 2010 to 2025
| BIAFW Stock | USD 0.27 0 0.74% |
Research And Ddevelopement To Revenue | First Reported 2010-12-31 | Previous Quarter 0.78 | Current Value 0.74 | Quarterly Volatility 107.83242371 |
Check BioAffinity Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioAffinity Technologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 301.4 K, Interest Expense of 40.6 K or Gross Profit of 955.9 K, as well as many indicators such as Price To Sales Ratio of 5.55, Dividend Yield of 0.0 or PTB Ratio of 2.5. BioAffinity financial statements analysis is a perfect complement when working with BioAffinity Technologies Valuation or Volatility modules.
BioAffinity | Research And Ddevelopement To Revenue |
Latest BioAffinity Technologies' Research And Ddevelopement To Revenue Growth Pattern
Below is the plot of the Research And Ddevelopement To Revenue of bioAffinity Technologies Warrant over the last few years. It is the ratio of a company's research and development expenses to its total revenue, indicating how much of the revenue is invested back into developing new products or services. BioAffinity Technologies' Research And Ddevelopement To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioAffinity Technologies' overall financial position and show how it may be relating to other accounts over time.
| Research And Ddevelopement To Revenue | 10 Years Trend |
|
Research And Ddevelopement To Revenue |
| Timeline |
BioAffinity Research And Ddevelopement To Revenue Regression Statistics
| Arithmetic Mean | 218.08 | |
| Geometric Mean | 88.68 | |
| Coefficient Of Variation | 49.45 | |
| Mean Deviation | 81.50 | |
| Median | 268.23 | |
| Standard Deviation | 107.83 | |
| Sample Variance | 11,628 | |
| Range | 268 | |
| R-Value | (0.68) | |
| Mean Square Error | 6,742 | |
| R-Squared | 0.46 | |
| Significance | 0 | |
| Slope | (15.34) | |
| Total Sum of Squares | 174,417 |
BioAffinity Research And Ddevelopement To Revenue History
About BioAffinity Technologies Financial Statements
BioAffinity Technologies investors use historical fundamental indicators, such as BioAffinity Technologies' Research And Ddevelopement To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioAffinity Technologies. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Research And Ddevelopement To Revenue | 0.78 | 0.74 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for BioAffinity Stock Analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.